Precision Medicine Companies

May 2023: Abbott Laboratories ABT has disclosed that the FDA has approved the FreeStyle Libre 2 and FreeStyle Libre 3 modified continuous glucose monitoring (CGM) system sensors and automated insulin delivery systems. By automatically modifying and dispensing the insulin administered by an insulin pump built on real-time glucose information from their FreeStyle Libre 2 or FreeStyle Libre 3 sensors, the company's AID systems assist people in their daily diabetes monitoring. The most recent innovation advances Abbott's Diabetes Care business line while maintaining its goal of giving diabetes patients an easy-to-use choice to use with their insulin pumps.

Sep 2023: Together, Oxford Nanopore Technologies plc, a provider of a new generation of nanopore-based molecular sensing technology, and bioMérieux SA, a pioneer in vitro diagnostic, have joined forces to improve health outcomes all over the world by examining opportunities to introduce nanopore sequencing to the market for infectious disease diagnostics. The businesses are jointly investigating ways to improve patient care by granting access to in vitro diagnostic (IVD) and clinical research based on nanopores. Long DNA or RNA fragments can be examined using a unique approach called nanopore-based sequencing. It functions by watching how an electrical current changes as nucleic acids travel via a protein nanopore. The precise DNA or RNA sequence is obtained by decoding the resulting signal. This technique is perfect for quickly and efficiently characterizing pathogens in clinical samples due to its unique, real-time, scalable properties.

• Abbott Laboratories (USA)


• Ab-Biotics Sa (USA)


• Almac Group Ltd. (UK)


• Asuragen Inc (USA)


• Biobase Gmbh (Germany)


• Biomérieux Sa(France)


• Caris Life Sciences (USA)


• Cepheid Inc. (USA)


• Celtics Healthcare Technologies Gmbh (Germany)


• GE Healthcare (USA)